The impact of psychiatric comorbidity on treatment discontinuation among individuals receiving medications for opioid use disorder

被引:21
|
作者
Friesen, Erik Loewen [1 ,2 ,3 ]
Kurdyak, Paul [1 ,3 ,4 ]
机构
[1] Univ Toronto, Inst Hlth Policy Management & Evaluat, 155 Coll St 4th Floor, Toronto, ON M5T 3M6, Canada
[2] Univ Toronto, Fac Med, Toronto, ON, Canada
[3] Ctr Addict & Mental Hlth, Toronto, ON, Canada
[4] ICES, Toronto, ON, Canada
关键词
Opioid use disorder; Psychiatry; Mental health; Medication for opioid use disorder; Treatment discontinuation; SUBSTANCE USE; TREATMENT COMPLETION; BUPRENORPHINE/NALOXONE TREATMENT; METHADONE; PREDICTORS; DEPENDENCE; DISPARITIES; ATTRITION; EPIDEMIC; DROPOUT;
D O I
10.1016/j.drugalcdep.2020.108244
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
摘要
Background: Psychiatric illness complicates the clinical course of opioid use disorder (OUD) including treatment using medication for OUD (MOUD). The purpose of this study was to assess the relationship between psychiatric comorbidity and MOUD discontinuation, stratified by whether the client dropped out of treatment or whether MOUD was terminated by the addiction facility. Methods: The study population consisted of individuals with OUD receiving MOUD. Data was derived from the 2015-2017 Treatment Episodes Dataset - Discharges (TEDS-D), which includes discharge records from addiction treatment centers across the United States. The association between psychiatric comorbidity and MOUD discontinuation (including client dropout and facility termination) was assessed using multivariable logistic regression models that included clinically relevant covariates (age, sex, race, education, employment status, living arrangement, prior addiction treatment, intravenous opioid use, primary opioid used at admission, polysubstance use, previous arrests, length of stay, and referral source). Results: Psychiatric comorbidity decreased the odds of client dropout (adjusted odds ratio (aOR): 0.88, 95 % confidence interval (CI): 0.86 - 0.89) but increased the odds of MOUD being terminated by the treatment facility (aOR: 1.59, 95 % CI: 1.56-1.63). The association between psychiatric comorbidity and MOUD discontinuation varied considerably between states. Conclusions: Individuals with psychiatric illness are slightly less likely to drop out of MOUD treatment but are more likely to have their treatment prematurely terminated by the treatment facility. This emphasizes the importance of considering psychiatric illness when providing OUD treatment and suggests that measures to improve MOUD retention for individuals with psychiatric illness are required.
引用
收藏
页数:8
相关论文
共 50 条
  • [1] Quality of primary care among individuals receiving treatment for opioid use disorder
    Spithoff, Sheryl
    Kiran, Tara
    Khuu, Wayne
    Kahan, Meldon
    Guan, Qi
    Tadrous, Mina
    Leece, Pamela
    Martins, Diana
    Gomes, Tara
    CANADIAN FAMILY PHYSICIAN, 2019, 65 (05) : 343 - 351
  • [2] Patterns of initiation and discontinuation of medications for opioid use disorder in commercially insured individuals in the US
    Seamans, Marissa J.
    Raman, Sudha R.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2023, 32 : 400 - 400
  • [3] Availability of Medications for the Treatment of Opioid Use Disorder Among Pregnant and Postpartum Individuals in US Jails
    Sufrin, Carolyn
    Kramer, Camille T.
    Terplan, Mishka
    Fiscella, Kevin
    Olson, Sarah
    Voegtline, Kristin
    Latkin, Carl
    JAMA NETWORK OPEN, 2022, 5 (01)
  • [4] Perceptions of medications, program settings, and drug use histories among individuals engaged in treatment for opioid use disorder
    Scherzer, Caroline
    Munoz, Paola Jimenez
    Ramsey, Susan
    Carey, Kate B.
    Ranney, Megan L.
    Clark, Seth
    Rich, Josiah
    Langdon, Kirsten J.
    JOURNAL OF ADDICTIVE DISEASES, 2024, 42 (01) : 24 - 32
  • [5] Perspectives Regarding Medications for Opioid Use Disorder Among Individuals with Mental Illness
    Tarn, Derjung M.
    Shih, Kevin J.
    Ober, Allison J.
    Hunter, Sarah B.
    Watkins, Katherine E.
    Martinez, Jeremy
    Montero, Alanna
    McCreary, Michael
    Leamon, Isabel
    Sheehe, John
    Bromley, Elizabeth
    COMMUNITY MENTAL HEALTH JOURNAL, 2023, 59 (02) : 345 - 356
  • [6] Perspectives Regarding Medications for Opioid Use Disorder Among Individuals with Mental Illness
    Derjung M. Tarn
    Kevin J. Shih
    Allison J. Ober
    Sarah B. Hunter
    Katherine E. Watkins
    Jeremy Martinez
    Alanna Montero
    Michael McCreary
    Isabel Leamon
    John Sheehe
    Elizabeth Bromley
    Community Mental Health Journal, 2023, 59 : 345 - 356
  • [7] Nonmedical use of gabapentin and opioid agonist medications in treatment-seeking individuals with opioid use disorder
    Ellis, Matthew S.
    Buttram, Mance E.
    Kasper, Zachary A.
    DRUG AND ALCOHOL DEPENDENCE, 2022, 234
  • [8] Psychiatric comorbidity and order of condition onset among patients seeking treatment for chronic pain and opioid use disorder
    Barry, Declan T.
    Beitel, Mark
    Cutter, Christopher J.
    Fiellin, David A.
    Madden, Lynn M.
    Lipkind, Nathan
    Bollampally, Pooja
    Liong, Christopher
    Schottenfeld, Richard S.
    DRUG AND ALCOHOL DEPENDENCE, 2021, 221
  • [9] Use and perceptions of Cannabidiol among individuals in treatment for opioid use disorder
    Kudrich, Christopher
    Chen, Rebecca
    Meng, Yuan
    Bachi, Keren
    Hurd, Yasmin L.
    HARM REDUCTION JOURNAL, 2024, 21 (01)
  • [10] Medications for Treatment of Opioid Use Disorder among Persons Living with HIV
    Fanucchi, Laura
    Springer, Sandra A.
    Korthuis, P. Todd
    CURRENT HIV/AIDS REPORTS, 2019, 16 (01) : 1 - 6